Literature DB >> 26575700

miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer.

Hong Tan1, Qingnan He2, Guanhui Gong3, Yixuan Wang1, Juanni Li1, Junpu Wang1, Ding Zhu1, Xiaoying Wu1.   

Abstract

Increasing evidence suggests that microRNAs (miRNAs) play a critical role in tumorigenesis. Decreased expression of miR‑382 has been observed in various types of cancers. However, the biological function of miRNA-382 in ovarian cancer is still largely unknown. Here, we found miR‑382 was downregulated in human ovarian cancer tissues and cell lines. miR‑382 inhibited ovarian cancer cell proliferation, migration, invasion and the epithelial-mesenchymal transition (EMT). Furthermore, we identified receptor tyrosine kinase orphan receptor 1 (ROR1) as a target of miR‑382, and miR‑382 rescued the promotion effect of ROR1 on migration, invasion and EMT process in SKOV3 and COV434 cells. Collectively, these findings revealed that miR‑382 inhibits migration and invision by targeting ROR1 through regulating EMT in ovarian cancer, and might serve as a tumor suppressor in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26575700     DOI: 10.3892/ijo.2015.3241

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  32 in total

1.  Repression of microRNA-382 inhibits glomerular mesangial cell proliferation and extracellular matrix accumulation via FoxO1 in mice with diabetic nephropathy.

Authors:  Shan Wang; Xin Wen; Xin-Rui Han; Yong-Jian Wang; Min Shen; Shao-Hua Fan; Juan Zhuang; Zi-Feng Zhang; Qun Shan; Meng-Qiu Li; Bin Hu; Chun-Hui Sun; Dong-Mei Wu; Jun Lu; Yuan-Lin Zheng
Journal:  Cell Prolif       Date:  2018-04-27       Impact factor: 6.831

Review 2.  Onco-GPCR signaling and dysregulated expression of microRNAs in human cancer.

Authors:  Nijiro Nohata; Yusuke Goto; J Silvio Gutkind
Journal:  J Hum Genet       Date:  2016-10-13       Impact factor: 3.172

Review 3.  MicroRNAs in gynecological cancers: Small molecules with big implications.

Authors:  Sanjeev K Srivastava; Aamir Ahmad; Haseeb Zubair; Orlandric Miree; Seema Singh; Rodney P Rocconi; Jennifer Scalici; Ajay P Singh
Journal:  Cancer Lett       Date:  2017-05-24       Impact factor: 8.679

4.  MiR-382 targets GOLM1 to inhibit metastasis of hepatocellular carcinoma and its down-regulation predicts a poor survival.

Authors:  Shukun Zhang; Wenmin Ge; Gangyong Zou; Lin Yu; Yongcun Zhu; Qiujing Li; Yujie Zhang; Zhanli Wang; Tao Xu
Journal:  Am J Cancer Res       Date:  2018-01-01       Impact factor: 6.166

5.  ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma.

Authors:  Yu-Zhu Zheng; Rui Ma; Jian-Kang Zhou; Cheng-Lin Guo; Yong-Sheng Wang; Zheng-Guang Li; Lun-Xu Liu; Yong Peng
Journal:  Sci Rep       Date:  2016-11-10       Impact factor: 4.379

6.  An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors.

Authors:  Satyen Harish Gohil; Solange Rosa Paredes-Moscosso; Micaela Harrasser; Marzia Vezzalini; Aldo Scarpa; Emma Morris; Andrew M Davidoff; Claudio Sorio; Amit Chunilal Nathwani; Marco Della Peruta
Journal:  Oncoimmunology       Date:  2017-05-17       Impact factor: 8.110

Review 7.  Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer.

Authors:  Yuliya Klymenko; Oleg Kim; M Sharon Stack
Journal:  Cancers (Basel)       Date:  2017-08-09       Impact factor: 6.639

8.  In silico model for miRNA-mediated regulatory network in cancer.

Authors:  Khandakar Tanvir Ahmed; Jiao Sun; William Chen; Irene Martinez; Sze Cheng; Wencai Zhang; Jeongsik Yong; Wei Zhang
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 13.994

9.  Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma.

Authors:  Tiziana de Cristofaro; Tina Di Palma; Amata Amy Soriano; Antonella Monticelli; Ornella Affinito; Sergio Cocozza; Mariastella Zannini
Journal:  Oncotarget       Date:  2016-07-05

10.  Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells.

Authors:  Zhengna Yin; Mengyun Gao; Sasa Chu; Yiping Su; Chunping Ye; Yiquan Wang; Zhuanqin Pan; Zhuming Wang; Huilin Zhang; Hua Tong; Jin Zhu
Journal:  Oncotarget       Date:  2017-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.